Barclays analyst Carter Gould maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,220.00.
Adding daratumumab to lenalidomide in maintenance therapy for multiple myeloma significantly reduced rates of minimal ...
The benefit-risk profile of finerenone (Kerendia) for heart failure and mildly reduced or preserved ejection fraction (HFmrEF ...
AbbVie Humira, Pfizer/BioNTech COVID-19 shot may not make top 10 pharma drugs in 2024, with Novo Nordisk Ozempic and ...
Bristol Myers gains FDA approval for a new schizophrenia drug. HHS declares a health emergency in Georgia due to Hurricane ...
Regeneron's R&D expenses are projected to reach $5 billion, but the business remains highly profitable. Read why I rate REGN ...
This summary of current health news includes FDA approvals for new drugs by Bristol Myers and GE HealthCare, public health ...
Regeneron Pharmaceuticals has purchased Quad’s shuttered printing plant in Saratoga Springs, sparking hopes for economic ...
WTEN Albany on MSN1d
Regeneron buys former Quad Graphics facilityThe best Western movie ever made, according to critics—and the rest of the top 50 'It's not taxed at all': Warren Buffett ...
On Friday, Regeneron Pharmaceuticals Inc (REGN) stock saw a modest uptick, ending the day at $1042.69 which represents a slight increase of $2.73 or 0.26% from the prior close of $1039.96. The stock ...
SARATOGA, N.Y. (WNYT)- Regeneron says they have purchased the sprawling former Quad Graphics site on Duplainville Road in ...
The U.S. FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating schizophrenia. The fixed dose combination of xanomeline-trospium is the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback